The monoclonal antibody market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028. The increasing prevalence of cancer and other chronic diseases and the growing cases of COVID-19 across various regions are the factors supporting the market proliferation. According to the World Cancer Research Fund and American Institute for Cancer, in 2020, ~18.1 million cancer cases were recorded worldwide, including 9.3 million cases in men and 8.8 million cases in women. Various types of monoclonal antibodies are being adopted for the treatment of different cancer types, and a few of these products are still in phases 2 and 3 clinical trials. Thus, the rising prevalence of chronic diseases has raised the demand for monoclonal antibodies across the world.
The monoclonal antibodies market is segmented on the basis of source, production method, indication application, and end-user. Based on source, the market is segmented into murine, chimeric, human, and humanized. The human segment is estimated to account for the largest market share during 2021-2028. The market growth of this segment is attributed to the rise on account of the integration of human monoclonal antibodies for the treatment of various kinds of infectious diseases. For instance, Regeneron launched FDA approved antibody cocktail casirivimab and imdevimab together for use in COVID-19. The drug has received Emergency Use Authorization (EUA) from FDA. It is used for the treatment of mild to moderate COVID-19 in adults as well as in pediatric patients at least 12 years of age and weighing at least 40kg. Moreover, an increase in their use in various chronic diseases and employment of advanced genetic engineering technology are among the significant factors driving the market segment's growth
By indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others. The cancer segment is expected to dominate the market during the forecast periodAdvancements related to the therapeutic application of monoclonal antibodies have enabled their successful implementation in the treatments of various cancer types, such as breast cancer, lung cancer, and colon cancer. Drugs based on these antibodies help in flagging cancer cells, triggering cell-membrane destruction, blocking immune system inhibitors, and so on. The FDA, in June 2020, approved two drugs-olaparib and rucaparib-for the treatment of prostate cancer. The drug is especially effective among men with prostate cancer conditions that have spread or metastasized and has stopped responding to standard hormone treatments, i.e., castration-resistant disease condition.
By end-user, the monoclonal antibody market is segmented into hospitals, research institutes, and others. The hospital segment holds the largest market share owing to the increasing adoption mABs as a preferred line of treatment against cancer.
The World Health Organization (WHO), World Cancer Research Fund International, Organization for Economic Co-operation and Development (OECD), Centers for Medicare & Medicaid Services (CMS), US Department of Health and Human Services, National Institute of Health (NIH), and American Institute of Cancer are among the primary and secondary sources referred to while preparing the report on the monoclonal antibodies market.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
 1.3.1 Global Monoclonal Antibodies (mAbs) Market - By Source
 1.3.2 Global Monoclonal Antibodies (mAbs) Market - By Production Method
 1.3.3 Global Monoclonal Antibodies (mAbs) Market - By Indication
 1.3.4 Global Monoclonal Antibodies (mAbs) Market - By Application
 1.3.5 Global Monoclonal Antibodies (mAbs) Market - By End-User
 1.3.6 Global Monoclonal Antibodies (mAbs) Market - By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Monoclonal Antibodies (mAbs) Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
 4.2.1 North America PEST Analysis
 4.2.2 Europe PEST Analysis
 4.2.3 Asia Pacific PEST Analysis
 4.2.4 Middle East And Africa PEST Analysis
 4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Monoclonal Antibodies (mAbs) Market - Key Market Dynamics
5.1 Market Drivers
 5.1.1 Rising Prevalence of Cancer and Other Chronic Diseases
 5.1.2 mABs Uptake Proves to be Effective During Pandemic Outbreak
5.2 Market Restraints
 5.2.1 Low Awareness, Accessibility, and High Cost
5.3 Market Opportunities
 5.3.1 Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity
5.4 Future Trends
 5.4.1 Strategic Research Collaborations
5.5 Impact Analysis
6. Monoclonal Antibodies (mAbs) Market- Global Analysis
6.1 Global Monoclonal Antibodies (mAbs) Market Revenue Forecast and Analysis
6.2 Global Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Global Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028- by Source
7.1 Overview
7.2 Global Monoclonal Antibodies (mAbs) Market, By Source, 2021 & 2028 (%)
7.3 Murine
 7.3.1 Overview
 7.3.2 Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Chimeric
 7.4.1 Overview
 7.4.2 Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Humanized
 7.5.1 Overview
 7.5.2 Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Human
 7.6.1 Overview
 7.6.2 Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
8. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - Production Method
8.1 Overview
8.2 Global Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2021 & 2028 (%)
8.3 In-Vivo
 8.3.1 Overview
 8.3.2 In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
8.4 In-Vitro
 8.4.1 Overview
 8.4.2 In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - Indication
9.1 Overview
9.2 Global Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2021 & 2028 (%)
9.3 Cancer
 9.3.1 Overview
 9.3.2 Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.4 Autoimmune Diseases
 9.4.1 Overview
 9.4.2 Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.5 Inflammatory Diseases
 9.5.1 Overview
 9.5.2 Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.6 Infectious Diseases
 9.6.1 Overview
 9.6.2 Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.7 Microbial Diseases
 9.7.1 Overview
 9.7.2 Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.8 Others
 9.8.1 Overview
 9.8.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - Application
10.1 Overview
10.2 Global Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2021 & 2028 (%)
10.3 Diagnostic Applications
 10.3.1 Overview
 10.3.2 Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.4 Therapeutic Applications
 10.4.1 Overview
 10.4.2 Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.5 Research Applications
 10.5.1 Overview
 10.5.2 Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - End-User
11.1 Overview
11.2 Global Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2021 & 2028 (%)
11.3 Hospitals
 11.3.1 Overview
 11.3.2 Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.4 Research Institutes
 11.4.1 Overview
 11.4.2 Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.5 Others
 11.5.1 Overview
 11.5.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
12. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 - Geographical Analysis
12.1 North America: Monoclonal Antibodies (mAbs) Market
 12.1.1 Overview
 12.1.2 North America: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
 12.1.3 North America: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
 12.1.4 North America: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
 12.1.5 North America: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
 12.1.6 North America: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
 12.1.7 North America: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
 12.1.8 North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
 12.1.8.1 US: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
 12.1.8.1.1 Overview
 12.1.8.1.2 US: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
 12.1.8.1.3 US: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
 12.1.8.1.4 US: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
 12.1.8.1.5 US: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
 12.1.8.1.6 US: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
 12.1.8.1.7 US: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
 12.1.8.2 Canada: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
 12.1.8.2.1 Overview
 12.1.8.2.2 Canada: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
 12.1.8.2.3 Canada: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
 12.1.8.2.4 Canada: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
 12.1.8.2.5 Canada: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
 12.1.8.2.6 Canada: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
 12.1.8.2.7 Canada: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
 12.1.8.3 Mexico: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
 12.1.8.3.1 Overview
 12.1.8.3.2 Mexico: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
 12.1.8.3.3 Mexico: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
 12.1.8.3.4 Mexico: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
 12.1.8.3.5 Mexico: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
 12.1.8.3.6 Mexico: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
 12.1.8.3.7 Mexico: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
12.2 Europe: Monoclonal Antibodies (mAbs) Market
 12.2.1 Overview
 12.2.2 Europe: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.3 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.2.4 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
 12.2.5 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
 12.2.6 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
 12.2.7 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
 12.2.8 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
 12.2.8.1 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.1.1 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.1.2 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.2.8.1.3 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
 12.2.8.1.4 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
 12.2.8.1.5 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
 12.2.8.1.6 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product (US$ Million)
 12.2.8.1.7 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
 12.2.8.2 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.2.1 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.2.2 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.2.8.2.3 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
 12.2.8.2.4 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
 12.2.8.2.5 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
 12.2.8.2.6 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Million)
 12.2.8.3 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.3.1 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.3.2 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.2.8.3.3 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
 12.2.8.3.4 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
 12.2.8.3.5 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
 12.2.8.3.6 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
 12.2.8.4 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.4.1 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.4.2 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.2.8.4.3 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
 12.2.8.4.4 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
 12.2.8.4.5 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
 12.2.8.4.6 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
 12.2.8.5 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.5.1 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.5.2 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.2.8.5.3 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
 12.2.8.5.4 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
 12.2.8.5.5 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
 12.2.8.5.6 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
 12.2.8.6 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.6.1 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.2.8.6.2 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source(US$ Million)
 12.2.8.6.3 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
 12.2.8.6.4 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication(US$ Million)
 12.2.8.6.5 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application(US$ Million)
 12.2.8.6.6 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
12.3 Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
 12.3.1 Overview
 12.3.2 Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.3 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
 12.3.4 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
 12.3.5 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
 12.3.6 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
 12.3.7 Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
 12.3.8 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
 12.3.8.1 China: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.1.1 China: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.1.2 China: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
 12.3.8.1.3 China: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
 12.3.8.1.4 China: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
 12.3.8.1.5 China: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
 12.3.8.1.6 China: Monoclonal Antibodies (mAbs) Market, by Product, 2019-2028 (USD Million)
 12.3.8.1.7 China: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
 12.3.8.2 Japan: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.2.1 Japan: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.2.2 Japan: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
 12.3.8.2.3 Japan: Monoclonal Antibodies (mAbs) Market, by Product, 2019-2028 (USD Million)
 12.3.8.2.4 Japan: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
 12.3.8.2.5 Japan: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
 12.3.8.2.6 Japan: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
 12.3.8.2.7 Japan: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
 12.3.8.3 India: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.3.1 India: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.3.2 India: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
 12.3.8.3.3 India: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
 12.3.8.3.4 India: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
 12.3.8.3.5 India: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
 12.3.8.3.6 India: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
 12.3.8.4 South Korea: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.4.1 South Korea: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.4.2 South Korea: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
 12.3.8.4.3 South Korea: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
 12.3.8.4.4 South Korea: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
 12.3.8.4.5 South Korea: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
 12.3.8.5 Australia: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.5.1 Australia: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.5.2 Australia: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
 12.3.8.5.3 Australia: Monoclonal Antibodies (mAbs) Market, By Production Method, 2019-2028 (USD Million)
 12.3.8.5.4 Australia: Monoclonal Antibodies (mAbs) Market, By Indication, 2019-2028 (USD Million)
 12.3.8.5.5 Australia: Monoclonal Antibodies (mAbs) Market, By Application, 2019-2028 (USD Million)
 12.3.8.5.6 Australia: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
 12.3.8.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.6.1 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
 12.3.8.6.2 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
 12.3.8.6.3 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
 12.3.8.6.4 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
 12.3.8.6.5 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
 12.3.8.6.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.4 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
 12.4.1 Overview
 12.4.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.4.3 Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.4.4 Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)
 12.4.5 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.4.6 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.4.7 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
 12.4.8 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
 12.4.8.1 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.4.8.1.1 Overview
 12.4.8.1.2 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.4.8.1.3 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.4.8.1.4 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
 12.4.8.1.5 UAE: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.1.6 UAE: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.1.7 UAE: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.4.8.2.1 Overview
 12.4.8.2.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.4.8.2.3 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.4.8.2.4 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
 12.4.8.2.5 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.2.6 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.2.7 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.4.8.3.1 Overview
 12.4.8.3.2 South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.4.8.3.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.4.8.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Production (US$ Million)
 12.4.8.3.5 South Africa: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.3.6 South Africa: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.4.8.3.7 South Africa: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.5 South And Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
 12.5.1 Overview
 12.5.2 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.5.3 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.5.4 South and Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
 12.5.5 South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.5.6 South and Central America: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.5.7 South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
 12.5.8 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
 12.5.8.1 Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.5.8.1.1 Overview
 12.5.8.1.2 Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.5.8.1.3 Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.5.8.1.4 Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
 12.5.8.1.5 Argentina: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.1.6 Argentina: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.1.7 Argentina: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.2 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.5.8.2.1 Overview
 12.5.8.2.2 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
 12.5.8.2.3 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.5.8.2.4 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
 12.5.8.2.5 Brazil: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.2.6 Brazil: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.2.7 Brazil: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.3 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market- Revenue and Forecast to 2028 (USD Mn)
 12.5.8.3.1 Overview
 12.5.8.3.2 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market- Revenue and Forecast to 2028 (USD Mn)
 12.5.8.3.3 Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
 12.5.8.3.4 Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
 12.5.8.3.5 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.3.6 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
 12.5.8.3.7 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
13. Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market
13.1 North America: Impact Assessment of COVID-19 Pandemic
13.2 Europe: Impact Assessment of COVID-19 Pandemic
13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
13.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
13.5 South and Central America: Impact Assessment of COVID-19 Pandemic
14. Monoclonal Antibodies (mAbs) Market-Industry Landscape
14.1 Overview
14.2 Growth Strategies Done by the Companies in the Market, (%)
14.3 Organic Developments
 14.3.1 Overview
14.4 Inorganic Developments
 14.4.1 Overview
15. Company Profiles
15.1 Novartis AG
 15.1.1 Key Facts
 15.1.2 Business Description
 15.1.3 Products and Services
 15.1.4 Financial Overview
 15.1.5 SWOT Analysis
 15.1.6 Key Developments
15.2 Pfizer Inc.
 15.2.1 Key Facts
 15.2.2 Business Description
 15.2.3 Products and Services
 15.2.4 Financial Overview
 15.2.5 SWOT Analysis
 15.2.6 Key Developments
15.3 GlaxoSmithKline plc.
 15.3.1 Key Facts
 15.3.2 Business Description
 15.3.3 Products and Services
 15.3.4 Financial Overview
 15.3.5 SWOT Analysis
 15.3.6 Key Developments
15.4 Amgen Inc.
 15.4.1 Key Facts
 15.4.2 Business Description
 15.4.3 Products and Services
 15.4.4 Financial Overview
 15.4.5 SWOT Analysis
 15.4.6 Key Developments
15.5 DAIICHI SANKYO COMPANY LIMITED
 15.5.1 Key Facts
 15.5.2 Business Description
 15.5.3 Products and Services
 15.5.4 Financial Overview
 15.5.5 SWOT Analysis
 15.5.6 Key Developments
15.6 F. HOFFMANN-LA ROCHE LTD.
 15.6.1 Key Facts
 15.6.2 Business Description
 15.6.3 Products and Services
 15.6.4 Financial Overview
 15.6.5 SWOT Analysis
 15.6.6 Key Developments
15.7 AstraZeneca
 15.7.1 Key Facts
 15.7.2 Business Description
 15.7.3 Products and Services
 15.7.4 Financial Overview
 15.7.5 SWOT Analysis
 15.7.6 Key Developments
15.8 Eli Lilly and Company.
 15.8.1 Key Facts
 15.8.2 Business Description
 15.8.3 Products and Services
 15.8.4 Financial Overview
 15.8.5 SWOT Analysis
 15.8.6 Key Developments
15.9 Bayer AG
 15.9.1 Key Facts
 15.9.2 Business Description
 15.9.3 Products and Services
 15.9.4 Financial Overview
 15.9.5 SWOT Analysis
 15.9.6 Key Developments
15.10 Bristol-Myers Squibb Company
 15.10.1 Key Facts
 15.10.2 Business Description
 15.10.3 Products and Services
 15.10.4 Financial Overview
 15.10.5 SWOT Analysis
 15.10.6 Key Developments
16. Appendix
16.1 About
16.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Monoclonal Antibodies (mAbs) Market, by Indication- Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Monoclonal Antibodies (mAbs) Market, by Application- Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Monoclonal Antibodies (mAbs) Market, by End-User- Revenue and Forecast to 2028 (US$ Million)
Table 6. US Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 7. US Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 8. US Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 9. US Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 10. US Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada: Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico: Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 18. Mexico Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 21. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 22. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 23. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 24. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 25. Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 26. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 27. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 28. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 29. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 30. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product US$ Million)
Table 31. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 32. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 33. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 34. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 35. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 36. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Million)
Table 37. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 38. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 39. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 40. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 41. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 42. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 43. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 44. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 45. Italy Monoclonal Antibodies (mAbs) Market Revenue
LIST OF FIGURES
The List of Companies - Monoclonal Antibody Market
1. Novartis AG
2. Pfizer Inc.
3. GlaxoSmithKline plc
4. Amgen, Inc
5. Daiichi Sankyo Company, Limited
6. F. Hoffmann-La Roche AG
7. AstraZeneca
8. Elli Lilly and Company
9. Bayer AG
10. Bristol-Myers Squibb Company